Page 1458 - Williams Hematology ( PDFDrive )

1432 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1433

1087. Zwaan CM, Meshinchi S, Radich JP, et al: FLT3 internal tandem duplication in 234 1119. Kwann HC, Huyck T: Thromboembolic and bleeding complication in acute leukemia.
children with acute myeloid leukemia: Prognostic significance and relation to cellular Expert Rev Hematol 3:719, 2010.
drug resistance. Blood 102:2387, 2002. 1120. Byrnes JJ, Baqueriro H, Gonzalez M, Henseley GT: Thrombotic thrombocytopenic
1088. Wheatley K, Burnett AK, Goldstone AH, et al: A simple robust, validated and highly purpura subsequent to acute myelogenous leukemia chemotherapy. Am J Hematol
predictive index for the determination of risk-directed therapy in acute myeloid leu- 21:299, 1986.
kaemia derived from the MRC AML 10 trial. Br J Haematol 107:69, 1999. 1121. Blumenfeld Z, Avivi I, Ritter M, Rowe JM: Preservation of fertility and ovarian func-
1089. Wells RJ, Arthur DC, Srivastava A, et al: Prognostic variables in newly diagnosed chil- tion and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc
dren and adolescents with acute myeloid leukemia. Leukemia 16:601, 2002. Gynecol Investig 6:229, 1999.
1090. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia 1122. Lopez Andreu JA, Fernandez PJ, Ferrisi Tortajada J, et al: Persistent altered spermato-
after induction therapy predicts relapse: Results from a prospective Children’s Cancer genesis in long-term childhood cancer survivors. Pediatr Hematol Oncol 17:21, 2000.
Group study of 252 patients with acute myeloid leukemia. Blood 101:3398, 2003. 1123. Relander T, Cavallin-Stahl E, Garwicz S, et al: Gonadal and sexual function in men
1091. Hann IM, Webb DK, Gibson BE, Harrison CJ: MRC trials in childhood acute myeloid treated for childhood cancer. Med Pediatr Oncol 35:52, 2000.
leukaemia. Ann Hematol 83 (Suppl 1):S108, 2004. 1124. Rossi BV, Missmer S, Correia KF, et al: Ovarian reserve in women treated for acute
1092. Coenen EV, Zwaan CM, Reinhardt D, et al: Pediatric acute myeloid leukemia with lymphocytic leukemia or acute myeloid leukemia with chemotherapy, but not stem
t(8;16)(p11;p13), a distinct clinical and biological entity: A collaborative study by the cell transplantation. ISRN Oncol 2012:956190, 2012.
International-Berlin-Frankfurt-Munster AML study group. Blood 122:2702, 2013. 1125. Molgaard-Hansen L, Skou AS, Juul A, et al: Pubertal development and fertility in
1093. Balgobind BV, Raimondi SC, Harbott J, et al: Novel prognostic subgroups in child- survivors of childhood acute myeloid leukemia treated with chemotherapy only: A
hood 11p23/MLL-rearranged acute myeloid leukemia: Results of an international NOPHO-AML study. Pediatr Blood Cancer 60:1988, 2013.
retrospective study. Blood 114:2489, 2009. 1126. Hinterberger-Fischer M, Kier P, Kalhs P, et al: Fertility, pregnancies and offspring
1094. Liang DC, Liu HC, Yang CP, et al: Cooperating gene mutations in childhood acute complications after bone marrow transplantation. Bone Marrow Transplant 7:5,
myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, 1991.
and DNMT3A. Blood 121:2988, 2013. 1127. Giri N, Vowels MR, Barr AL, Mameghan H: Successful pregnancy after total body
1095. Woods WG, Neudorf S, Gold S, et al: A comparison of allogeneic bone marrow trans- irradiation and bone marrow transplantation for acute leukaemia. Bone Marrow
plantation, autologous bone marrow transplantation, and aggressive chemotherapy Transplant 10:93, 1992.
in children with acute myeloid leukemia in remission: A report from the Children’s 1128. Lemez P, Urbánek V: Chemotherapy for acute myeloid leukemias with cytosine arabi-
Cancer Group. Blood 97:56, 2001. noside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthe-
1096. Pession A, Masetti R, Rizzari C, et al: Results of the AIEOP AML 2002/01 multicenter nozoospermia or amenorrhea in middle-aged patients. Neoplasma 52:398, 2005.
prospective trial for the treatment of children with acute myeloid leukemia. Blood 1129. Maguire LC, Dick FR, Sherman BM: The effects of anti-leukemic therapy on gonadal
122:170, 2013. histology in adult males. Cancer 48:1967, 1981.
1097. Kawasaki H, Isoyama K, Eguchi M, et al: Superior outcome of infant acute myeloid 1130. Matthews JH, Wood JK: Male fertility during chemotherapy for acute leukemia. N
leukemia with intensive chemotherapy: Results of the Japan Infant Leukemia Study Engl J Med 303:1235, 1980.
Group. Blood 98:3589, 2001. 1131. Branvall E, Derolf AR, Johansson E, et al: Self-reported fertility in long-term survivors
1098. Chessels JM, Harrison CJ, Kempski H, et al: Clinical features, cytogenetics, and out- of acute myeloid leukemia. Ann Hematol 93:1491, 2014.
come in acute lymphoblastic and myeloid leukemia of infancy: Report from the MRC 1132. Cheson BD, Bennett J, Kopecky KJ, et al: Revised recommendations of the Interna-
Childhood Leukemia working party. Leukemia 16:776, 2002. tional Working Group for Diagnosis, Standardization of Response Criteria, Treatment
1099. Rocha V, Cornish J, Sievers EL, et al: Comparison of outcomes of unrelated bone Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leuke-
marrow and umbilical cord blood transplants in children with acute leukemia. Blood mia. J Clin Oncol 21:4642, 2003.
97:2962, 2001. 1133. Lichtman MA: Does a diagnosis of myelogenous leukemia require 20% marrow mye-
1100. Leung W, Hudson MM, Strickland DK, et al: Late effects of treatment in survivors of loblasts, and does <5% marrow myeloblasts represent a remission? The history and
childhood acute myeloid leukemia. J Clin Oncol 18:3273, 2000. ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.
1101. Leung W, Ribiero RC, Hudson MM, et al: Second malignancy after treatment of child- Oncologist 18:973, 2013.
hood acute myeloid leukemia. Leukemia 15:41, 2001. 1134. Walter RB, Kantarjian HM, Hunag X, et al: Effect of complete remission and responses
1102. Verhagen C, Stalpers LJ, dePauw BE, Haanen C: Drug-induced skin reactions in less than complete remission on survival in acute myeloid leukemia: A combined
patients with acute non-lymphocytic leukaemia. Eur J Haematol 38:225, 1987. Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Ander-
1103. Kapusta L, Groot-Loonen J, Thijssen JM, et al: Regional cardiac wall motion abnormal- son Cancer Center study. J Clin Oncol 28:1766, 2010.
ities during and shortly after anthracyclines therapy. Med Pediatr Oncol 41:426, 2003. 1135. Chen Y, Cortes J, Estrov Z, et al: Persistence of cytogenetic abnormalities at complete
1104. Sawyer DB: Anthracyclines and heart failure. N Engl J Med 368:1154, 2013. remission after induction in patients with acute myeloid leukemia: Prognostic sig-
1105. Benvenuto GM, Ometto R, Fontanelli A, et al: Chemotherapy-related cardiotoxicity: nificance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol
New diagnostic and preventive strategies. Ital Heart J 4:655, 2003. 29:2507, 2011.
1106. Dietz B, van der Hem KG: Late-onset cardiotoxicity of chemotherapy and radiother- 1136. Wahlin A, Markevarn B, Gololeva I, et al: Improved outcome in adult acute myeloid
apy. Neth J Med 61:228, 2003. leukemia is almost entirely restricted to young patients and associated stem cell trans-
1107. Theodoulou M, Hudis C: Cardiac profiles of liposomal anthracyclines: Greater cardiac plantation. Eur J Haematol 68:54, 2002.
safety versus conventional doxorubicin? Cancer 100:2052, 2004. 1137. Lichtman MA, Rowe JM: The relationship of patient age to the pathobiology of the
1108. Swain SM, Vici P: The current and future role of dexrazoxane as a cardioprotectant in clonal myeloid disease. Semin Oncol 31:185, 2004.
anthracycline treatment: Expert panel review. J Cancer Res Clin Oncol 130:1, 2004. 1138. Kayser S, Dohen K, Krauter, et al: The impact of therapy-related acute myeloid leu-
1109. Anderson LA, Pfeiffer R, Warren JL, et al: Hematopoietic malignancies associated kemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood
with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 17:3069, 2008. 117:2137, 2011.
1110. Kojima H, Abei M, Takei N, et al: Fatal reactivation of hepatitis B virus following cyto- 1139. Yanada M, Garcia-Manero G, Borthakur G, et al: Potential cure of acute myeloid
toxic chemotherapy for acute myelogenous leukemia: Fibrosing cholestatic hepatitis. leukemia: Analysis of 1069 consecutive patients in first complete remission. Cancer
Eur J Haematol 69:101, 2002. 110:2756, 2007.
1111. Ishiga K, Kawatani T, Suou T, et al: Fulminant hepatitis type B after chemotherapy in 1140. Walter RB, Othus M, Borthakur G, et al: Prediction of early death after induction
a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A
J Hematol 73:115, 2001. novel paradigm for treatment assignment. J Clin Oncol 29:4417, 2011.
1112. Bianco E, Marcucci F, Mele A, et al: Prevalence of hepatitis C virus infection in lymph- 1141. Fialkow PJ, Singer JW, Roskind WH, et al: Clonal development, stem cell differenti-
oproliferative diseases other than B-cell non-Hodgkin’s lymphoma, and in myeloprolif- ation and the nature of clinical remissions in acute nonlymphocytic leukemia: Stud-
erative diseases: An Italian Multi-Center case-control study. Haematologica 89:70, 2004. ies of patients heterozygous for glucose-6-phosphate dehydrogenase. N Engl J Med
1113. Zuckerman E, Zuckerman T, Douer D, et al: Liver dysfunction in patients infected 317:468, 1987.
with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Can- 1142. Bartram CR, Ludwig W-D, Hiddemann W, et al: Acute myeloid leukemia: Analysis
cer 15:1224, 1998. of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia
1114. Colović M, Lazarević V, Colović R, et al: Hepatosplenic candidiasis after neutropenic 3:247, 1989.
phase of acute leukaemia. Med Oncol 16:139, 1999. 1143. Fialkow PJ, Janssen JWG, Bartram CR: Clonal remissions in acute nonlymphocytic
1115. Teefey SA, Montana MA, Goldfogel GA, Shuman WP: Sonographic diagnosis of neu- leukemia: Evidence for a multistep pathogenesis of the malignancy. Blood 77:1415,
tropenic typhlitis. AJR Am J Roentgenol 149:731, 1987. 1991.
1116. Keidan RD, Fanning J, Gatenby RA, Weese JL: Recurrent typhlitis. A disease resulting 1144. Busque L, Gilliland DG: Clonal evolution in acute myeloid leukemia. Blood 82:337,
from aggressive chemotherapy. Dis Colon Rectum 32:206, 1989. 1993.
1117. Zuckerman T, Ganzel C, Tallman MS, et al: How I treat hematologic emergencies in 1145. Gale RE, Wheadon H, Goldstone AH, et al: Frequency of clonal remission in acute
adults with acute leukemia. Blood 120:1993, 2012. myeloid leukaemia. Lancet 341:138, 1993.
1118. De Stefano V, Sora F, Rossi E, et al: The risk of thrombosis in patients with acute leuke- 1146. Killman SA: Acute leukemia: Development, remission/relapse pattern, relationship
mia: Occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost between normal and leukaemic haemopoiesis, and the “sleeper-to-feeder” stem cell
3:1985, 2004. hypothesis. Baillieres Clin Haematol 4:577, 1991.

Kaushansky_chapter 88_p1373-1436.indd 1433 9/21/15 11:02 AM